← back to search

Adrian Dunlop

New South Wales Department of Health ·
Area of research
Epidemiology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Medicine, Buprenorphine, Randomized controlled trial, Opioid, Heroin, and Cannabis.
h-index
citations
1,752
works
25
NIH funding
primary concept
email

Recent publications

96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial
International Journal of Drug Policy 2024cited by 20position: middledoi
Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice
Ophthalmology and Therapy 2024cited by 12position: middledoi
Cohort profile: POPPY II – a population-based cohort examining the patterns and outcomes of prescription opioid use in New South Wales, Australia
BMJ Open 2023cited by 5position: middledoi
The<i>Staphylococcus aureus</i>Network Adaptive Platform Trial Protocol: New Tools for an Old Foe
Clinical Infectious Diseases 2022cited by 95position: middledoi
Willingness of people who inject drugs to participate in a randomised controlled trial involving financial incentives to initiate hepatitis C treatment
Drug and Alcohol Dependence 2022cited by 10position: middledoi
Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine
JAMA Network Open 2021cited by 121position: middledoi
Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients’ experiences in Australia
Drug and Alcohol Dependence 2021cited by 68position: middledoi
Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence
International Journal of Drug Policy 2021cited by 52position: middledoi
Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings
Addiction 2021cited by 51position: firstdoi
Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic
Harm Reduction Journal 2020cited by 282position: firstdoi
Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study
Clinical Infectious Diseases 2020cited by 73position: middledoi
Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder
Addiction 2019cited by 110position: middledoi
Nabiximols for the Treatment of Cannabis Dependence
JAMA Internal Medicine 2019cited by 104position: middledoi
Antenatal care for alcohol consumption during pregnancy: pregnant women’s reported receipt of care and associated characteristics
BMC Pregnancy and Childbirth 2019cited by 50position: middledoi
Effect of increasing the delivery of smoking cessation care in alcohol and other drug treatment centres: a cluster‐randomized controlled trial
Addiction 2019cited by 16position: middledoi
Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration
Ophthalmology 2017cited by 96position: middledoi
Effectiveness and cost-effectiveness of unsupervised buprenorphine-naloxone for the treatment of heroin dependence in a randomized waitlist controlled trial
Drug and Alcohol Dependence 2017cited by 34position: firstdoi
An organisational change intervention for increasing the delivery of smoking cessation support in addiction treatment centres: study protocol for a randomized controlled trial
Trials 2016cited by 10position: middledoi
Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study
Addiction 2015cited by 68position: middledoi
‘<i>The lesser of two evils</i>’: A qualitative study of staff and client experiences and beliefs about addressing tobacco in addiction treatment settings
Drug and Alcohol Review 2015cited by 29position: middledoi
Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal
JAMA Psychiatry 2014cited by 263position: middledoi
Changes in cigarette and alcohol use during cannabis abstinence
Drug and Alcohol Dependence 2014cited by 55position: middledoi
Prevalence of unhealthy alcohol use in hospital outpatients
Drug and Alcohol Dependence 2014cited by 13position: middledoi
Assessment and Treatment of Hepatitis C Virus Infection Among People Who Inject Drugs in the Opioid Substitution Setting: ETHOS Study
Clinical Infectious Diseases 2013cited by 107position: middledoi
An examination of barriers to Nurse Practitioner endorsement in senior rural drug and alcohol nurses in New South Wales
Collegian Journal of the Royal College of Nursing Australia 2012cited by 8position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Nicholas Lintzeris · St. Leonards Hospital10 papers (2014–2024)Paul Haber · Alcohol and Drug Foundation7 papers (2013–2021)Jason Grebely · UNSW Sydney6 papers (2013–2024)Gregory J. Dore · UNSW Sydney6 papers (2013–2024)Michael Farrell · Arizona State University5 papers (2015–2024)Mark Montebello · The University of Sydney4 papers (2014–2024)Maryam Alavi · UNSW Sydney4 papers (2013–2022)John Attia · University of Newcastle Australia4 papers (2014–2021)Louisa Degenhardt · UNSW Sydney4 papers (2020–2024)Christopher Oldmeadow · University of Newcastle Australia3 papers (2017–2021)Carla Treloar · UNSW Sydney3 papers (2013–2020)Anthony Shakeshaft · UNSW Sydney3 papers (2015–2019)Billie Bonevski · University of Queensland3 papers (2015–2019)Jan Copeland · UNSW Sydney3 papers (2014–2019)Ashleigh Guillaumier · Flinders University3 papers (2015–2019) · 3 papers (2015–2019) · 3 papers (2015–2019)Craig Sadler · New South Wales Department of Health3 papers (2014–2017) · 2 papers (2021–2024)D. B. A. Silk · UNSW Sydney2 papers (2020–2022)